-1768251348562.webp&w=3840&q=75)
2025 MaTOS Lung | Session XI | Keynote Presentation: Next Generation Approaches for Tailoring Treatments for EGFR and HER-2 Mutant NSCLC
0% Complete
Course Overview
Dr. Heymach reviewed lung cancer treatment evolution, stressing next-gen strategies beyond single mutations, co-mutation complexity, resistance, and promising new EGFR/HER2-targeted drugs.
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- Jan 10, 2026
- Last Review
- Jan 10, 2026
- Expires
- Dec 31, 2026
Objectives
NA
Target Audience
Physicians
Faculty & Disclosure
Faculty
John Heymach, MD, PhD
Disclosure
<p></p>
Accreditation
NA
-1773064915543.webp&w=3840&q=75)
-1773064818174.webp&w=3840&q=75)